An interventional study of SpO2 Sensor in SpO2 (Peripheral Oxygen Saturation) Measurement Validation and SpO2, sponsored by GE Healthcare. Not yet recruiting at 1 site in United States. Open to participants aged 29 Days to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by GE Healthcare · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data, performance across skin tones, and user feedback.
This prospective clinical study evaluates a pulse oximetry sensor in hospitalized infants (28 days to 23 months) and children (2-12 years) under routine clinical conditions. The primary objective is to assess the accuracy and agreement of SpO₂ measurements compared with reference SaO₂ values obtained from CO-oximetry analysis of simultaneously drawn arterial blood, using methods aligned with ISO 80601-2-61: 2026 3rd edition published in April 2026.
Secondary objectives include measuring the proportion of time the device produces invalid or unusable data to assess reliability for clinical use. The safety objective is to collect safety information, including type and number of AEs, SAEs, and device issues. Results may support product development, regulatory submissions, and marketing activities.
GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants participating in this study will be connected to SpO2 sensors. SpO2 data will be independently collected from each sensor and paired with simultaneous arterial blood sample SaO₂ values. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
Device: SpO2 Sensor
SpO2 sensors use red and infrared LED light to estimate the arterial oxygen saturation.
Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 values
The collection of SpO2 percentage sensor data with simultaneous SaO2 values percentage from each subject enrolled in the study.
Time frame: From enrollment to the end of standard of care arterial cannulation, approximately 1 week.
Incidence of Safety Events
Analysis of adverse events will be listed per subject, summarized with counts and percentages of events, and summarized with counts and percentages of subjects with events.
Time frame: 4 months
Plan to share: No
Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.